CHF261.90
1.67% today
SIX Swiss Exchange, May 12, 05:30 pm CET
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Roche Stock price

CHF257.60
+22.20 9.43% 1M
-7.90 2.98% 6M
+2.10 0.82% YTD
+35.30 15.88% 1Y
-88.40 25.55% 3Y
-87.15 25.28% 5Y
-9.50 3.56% 10Y
SIX Swiss Exchange, Closing price Fri, May 09 2025
-2.30 0.89%
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Key metrics

Market capitalization CHF204.90b
Enterprise Value CHF228.33b
P/E (TTM) P/E ratio 24.79
EV/FCF (TTM) EV/FCF 14.59
EV/Sales (TTM) EV/Sales 3.77
P/S ratio (TTM) P/S ratio 3.39
P/B ratio (TTM) P/B ratio 6.45
Dividend yield 3.77%
Last dividend (FY24) CHF9.70
Revenue growth (TTM) Revenue growth 3.03%
Revenue (TTM) Revenue CHF60.50b
EBIT (operating result TTM) EBIT CHF17.61b
Free Cash Flow (TTM) Free Cash Flow CHF15.65b
EPS (TTM) EPS CHF10.32
P/E forward 14.16
P/S forward 3.23
EV/Sales forward 3.60
Show more

Create a Free Account to create an Roche alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Roche forecast:

10x Buy
42%
10x Hold
42%
4x Sell
17%

Analyst Opinions

24 Analysts have issued a Roche forecast:

Buy
42%
Hold
42%
Sell
17%

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
60,495 60,495
3% 3%
100%
- Direct Costs 16,082 16,082
2% 2%
27%
44,413 44,413
4% 4%
73%
- Selling and Administrative Expenses 10,335 10,335
5% 5%
17%
- Research and Development Expense 13,042 13,042
1% 1%
22%
21,036 21,036
6% 6%
35%
- Depreciation and Amortization 3,423 3,423
1% 1%
6%
EBIT (Operating Income) EBIT 17,613 17,613
8% 8%
29%
Net Profit 8,277 8,277
28% 28%
14%

In millions CHF.

Don't miss a Thing! We will send you all news about Roche directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roche Stock News

Neutral
PRNewsWire
about 2 hours ago
An investment of up to $550 million by 2030 will establish the Indianapolis site as a hub for manufacturing of Roche's continuous glucose monitoring solution. Expansion will create hundreds of jobs while also enhancing U.S. production capabilities.
Positive
Reuters
about 3 hours ago
Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in Holly Springs, North Carolina.
Neutral
Business Wire
about 4 hours ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs, NC. The project will add more than 400 high-wage manufacturing jobs when the site is operational and more than 1,500 construction jobs ...
More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Thomas Schinecker
Employees 103,249
Founded 1896
Website www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today